Macquarie Group’s BioAtla BCAB Stock Holding History

Macquarie Group’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-45	Closed	-$3.11K	–	1675
2024 Q2	$3.11K	Buy	+45	New	+$5.35K	﹤0.01%	1764

Other funds holding BCAB

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Macquarie Group's BCAB Position: Q3 2024 in Review

Macquarie Group sold out of BioAtla (BCAB) in Q3 2024, closing a stake of 45 shares — an estimated $3.11K sold.

Macquarie Group first reported a position in BCAB in Q2 2024 and held it in 1 quarter. The position peaked at $3.11K in Q2 2024. 63 funds tracked by Wall St. Rank hold BCAB as of Q3 2024.

Macquarie Group reported no remaining BioAtla position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 45 BioAtla shares in Q3 2024, an estimated $3.11K.
Macquarie Group first reported a position in BioAtla in Q2 2024 and held it in 1 quarter.
Macquarie Group's BioAtla position peaked at $3.11K in Q2 2024.
63 funds tracked by Wall St. Rank held BioAtla as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.